Oxford Asset Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Oxford Asset Management’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-40,016	Closed	-$55K	–	2122
2018 Q2	$55K	Buy	40,016 +5,465	+16%	+$8.37K	﹤0.01%	1653
2018 Q1	$50K	Buy	34,551 +11,351	+49%	+$23.7K	﹤0.01%	1559
2017 Q4	$53K	Buy	+23,200	New	+$58.7K	﹤0.01%	1556
2017 Q1	–	Sell	-48,790	Closed	-$224K	–	1581
2016 Q4	$224K	Buy	+48,790	New	+$201K	0.01%	691

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oxford Asset Management's AST Position: Q3 2018 in Review

Oxford Asset Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2018, closing a stake of 40,016 shares — an estimated $55K sold.

Oxford Asset Management first reported a position in AST in Q4 2016 and held it in 4 quarters. The position peaked at $224K in Q4 2016. 54 funds tracked by Wall St. Rank hold AST as of Q3 2018.

Oxford Asset Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2018 after selling out during the quarter.
Oxford Asset Management sold 40,016 Asterias Biotherapeutics Inc. Series A shares in Q3 2018, an estimated $55K.
Oxford Asset Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2016 and held it in 4 quarters.
Oxford Asset Management's Asterias Biotherapeutics Inc. Series A position peaked at $224K in Q4 2016.
54 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2018.

Based on Oxford Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.